Eric Ostertag - 31 Dec 2022 Form 5 Insider Report for Poseida Therapeutics, Inc.

Role
Director
Signature
/s/ Harry J. Leonhardt, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
31 Dec 2022
Net transactions value
$0
Form type
5
Filing time
17 Jan 2023, 20:18:30 UTC
Previous filing
10 Aug 2022
Next filing
03 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding PSTX Common Stock 839,096 31 Dec 2022 Direct F1
holding PSTX Common Stock 3,659,503 31 Dec 2022 See footnote F2
holding PSTX Common Stock 580,292 31 Dec 2022 See footnote F3
holding PSTX Common Stock 961,445 31 Dec 2022 See footnote F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 272 shares acquired by the reporting person under the Issuer's 2020 Employee Stock Purchase Plan on September 20, 2022.
F2 The shares are held in the name of the Eric Ostertag Living Trust dated March 30, 2016, of which the reporting person is the sole trustee.
F3 The shares are held in the name of Twin Prime Investments, an entity wholly owned by the reporting person.
F4 The shares are held in the name of the Ostertag Family Trust dated March 30, 2016, of which the reporting person is a trustee.

Remarks:

The shares of the Issuer's common stock held by Titan LLC, which is owned by the Ostertag Descendants' Trust, of which the reporting person's minor daughter is the sole beneficiary, are not included in this report as the reporting person does not have, or share, voting or investment control over the shares held by Titan LLC and thus does not beneficially own such shares for purposes of Section 16 or any other purpose.